Literature DB >> 3040286

Elevation of plasma levels of fluorinated pyrimidines by guanosine 5'-monophosphate.

M Iigo, Z Yamaizumi, S Nishimura, A Hoshi.   

Abstract

The plasma concentration of 5-fluorouracil (FUra) following the i.v. administration of FUra and guanosine 5'-monophosphate (GMP) or guanosine 5'-triphosphate (GTP) was markedly elevated. These values were more than 5-fold higher than those obtained with FUra alone over 60 min after administration. The elevation of plasma levels corresponded to the dose of GMP. Higher levels of FUra were maintained in the plasma after injection of inosine or inosine 5'-monophosphate in combination with FUra than after FUra alone, but they were lower than those induced by GMP or GTP. Moreover, plasma levels of two other fluorinated pyrimidines, 5'-deoxy-5-fluorouridine (DFUR) and 5-fluoro-2'-deoxycytidine (FdCyd), were also elevated by GMP. The combination of DFUR and GMP resulted in higher plasma levels of DFUR itself and FUra (12- and 10-fold, respectively, 30 min after treatment). After administration of FdCyd plus GMP, the plasma levels of FdCyd, 5-fluoro-2'-deoxyuridine, which is converted from FdCyd by cytidine deaminase, and FUra were 2-, 6-, and 7-fold higher, respectively, than those after FdCyd alone 30 min after treatment. Thus, GMP is the most effective compound for the maintenance of high plasma levels of fluorinated pyrimidines.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3040286     DOI: 10.1007/BF00252949

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

1.  Studies of fluorinated pyrimidines. XV. Inhibition of the incorporation of formate-C14 into DNA thymine of Ehrlich ascites carcinoma cells by 5-fluoro-2'-deoxyuridine-5'-monophosphate and related compounds.

Authors:  K L MUKHERJEE; C HEIDELBERGER
Journal:  Cancer Res       Date:  1962-08       Impact factor: 12.701

2.  Potentiation of the chemotherapeutic action of 5'-deoxy-5-fluorouridine in combination with guanosine and related compounds.

Authors:  M Iigo; M Miwa; H Ishitsuka; K Nitta
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Incorporation of 5-fluorodeoxycytidine and metabolites into nucleic acids of human MCF-7 breast carcinoma cells.

Authors:  J Kaysen; D Spriggs; D Kufe
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

4.  Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil.

Authors:  S Fujii; K Ikenaka; M Fukushima; T Shirasaka
Journal:  Gan       Date:  1978-12

5.  Effect of guanosine on antitumor activity of fluorinated pyrimidines against P 388 leukemia.

Authors:  M Iigo; A Hoshi
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

6.  Effect of coadministration of thymine or thymidine on the antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil.

Authors:  S Fujii; S Kitano; K Ikenaka; M Fukushima; H Nakamura; Y Maehara; T Shirasaka
Journal:  Gan       Date:  1980-02

7.  Potentiation of the chemotherapeutic action of 5-fluorouracil by combination with cytidine or guanosine on HRS-sarcoma.

Authors:  H Osswald; M Youssef
Journal:  J Cancer Res Clin Oncol       Date:  1979-04-12       Impact factor: 4.553

8.  Potentiation of the chemotherapeutic effect of 5-fluorouracil by combination with guanosine 5'-monophosphate.

Authors:  M Iigo; Y Nakajima; K Kuretani; A Hoshi
Journal:  Gan       Date:  1983-04

9.  Modulation of 5-fluorouracil metabolism by thymidine. In vivo and in vitro studies on RNA-directed effects in rat liver and hepatoma.

Authors:  C Engelbrecht; I Ljungquist; L Lewan; T Yngner
Journal:  Biochem Pharmacol       Date:  1984-03-01       Impact factor: 5.858

10.  Effect of pyrimidines, purines and their nucleosides on antitumor activity of 5-fluorouracil against L-1210 leukemia.

Authors:  M Iigo; N Ando; A Hoshi; K Kuretani
Journal:  J Pharmacobiodyn       Date:  1982-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.